Here’s Why H.C. Wainwright Upgraded Prime Medicine (PRME) To “Buy”

Here’s Why H. C. Wainwright Upgraded Prime Medicine (PRME) To “Buy” Faheem Tahir Mon, July 6, 2026 at 12:07 AM GMT+2 2 min read PRME Prime Medicine, Inc.

(NASDAQ: PRME ) ranks among the overlooked penny stocks to buy right now , supported by strong upside potential. Multiple regulatory clearances across its gene-editing pipeline are prompting analysts to turn more constructive on the stock. Here’s Why H.

C. Wainwright Upgraded Prime Medicine (PRME) To “Buy” On June 29, 2026, H. C.

Wainwright upgraded Prime Medicine, Inc. (NASDAQ:PRME) to "Buy" from "Neutral" with a price target of $8. The upgrade came after New Zealand's Medicines and Medical Devices Safety Authority accepted the clinical trial application for PM577a, the company's investigational therapy for Wilson's disease.

The firm called the clearance a meaningful de-risking event, noting it marks the first clinical authorization for an in vivo prime editing therapy from Prime Medicine. That clearance, announced by the company on June 18, 2026, enables Prime Medicine, Inc. (NASDAQ:PRME) to begin a global Phase 1/2 study evaluating PM577a in adults and adolescents with Wilson Disease.

CEO Allan Reine called the milestone a defining moment, pointing to PM577a's potential to correct the disease at the genomic level with a one-time therapy. Chief Medical Officer Mohammed Asmal said the trial design draws on the company's preclinical work, with proof-of-concept data expected in 2027. Meanwhile, on June 22, 2026, the FDA granted Regenerative Medicine Advanced Therapy designation to PM359, Prime Medicine, Inc.

(NASDAQ:PRME)'s stem cell therapy for p47phox-deficient chronic granulomatous disease (CGD), based on Phase 1/2 clinical data published in The New England Journal of Medicine. Reine said the designation supports engagement with the FDA toward a future Biologics License Application. Prime Medicine, Inc.

(NASDAQ:PRME) is a biotechnology company that delivers genetic medicines to address the spectrum of diseases by deploying gene editing technology. While we acknowledge the potential of PRME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years . Disclosure: None. Follow Insider Monkey on Google News .